Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent INK128 in Subjects With Advanced Malignancies, Followed by an Expansion in Subjects With Measurable Disease

Next Previous
Trial Profile

A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent INK128 in Subjects With Advanced Malignancies, Followed by an Expansion in Subjects With Measurable Disease

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 17 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sapanisertib (Primary)
  • Indications Adenocarcinoma; Bladder cancer; Endometrial cancer; Renal cancer; Renal cell carcinoma; Solid tumours; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Takeda Oncology

Most Recent Events

  • 19 Feb 2019 Status changed from active, no longer recruiting to completed.
  • 07 Jan 2019 Planned End Date changed from 31 Oct 2018 to 31 Jan 2019.
  • 24 Aug 2018 Planned End Date changed from 30 Jun 2018 to 31 Oct 2018.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top